Pharmacokinetics and Pharmacodynamics with Extended Dosing of CC-486 in Patients with Hematologic Malignancies.

by Eric Laille, Tao Shi, Guillermo Garcia-Manero, Christopher R Cogle, Steven D Gore, Joel Hetzer, Keshava Kumar, Barry Skikne, Kyle J MacBeth
Published 2015-01-01

A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines.

by Paul W Hollenbach, Aaron N Nguyen, Helen Brady, Michelle Williams, Yuhong Ning, Normand Richard, Leslie Krushel, Sharon L Aukerman, Carla Heise, Kyle J MacBeth
Published 2010-01-01

Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia

by Feng Wang, Kiyomi Morita, Courtney D. DiNardo, Ken Furudate, Tomoyuki Tanaka, Yuanqing Yan, Keyur P. Patel, Kyle J. MacBeth, Bin Wu, Guowen Liu, Mark Frattini, Jairo A. Matthews, Latasha D. Little, Curtis Gumbs, Xingzhi Song, Jianhua Zhang, Erika J. Thompson, Tapan M. Kadia, Guillermo Garcia-Manero, Elias Jabbour, Farhad Ravandi, Kapil N. Bhalla, Marina Konopleva, Hagop M. Kantarjian, P. Andrew Futreal, Koichi Takahashi
Published 2021-05-01